{"denoms":[{"counts":[{"groupId":"BG000","value":"306"},{"groupId":"BG001","value":"305"},{"groupId":"BG002","value":"611"}],"units":"Participants"}],"groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"BG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"BG001","title":"Dasatinib 70 mg BID"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]}],"title":"Less than (<) 21 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"184"}]}],"title":"21 - 45 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"143"},{"groupId":"BG001","value":"143"},{"groupId":"BG002","value":"286"}]}],"title":"46 - 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"114"}]}],"title":"66 - 75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}]}],"title":"Greater than (>) 75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Not Reported"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"267"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"173"},{"groupId":"BG001","value":"171"},{"groupId":"BG002","value":"344"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"76"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"35"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"235"},{"groupId":"BG001","value":"236"},{"groupId":"BG002","value":"471"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"22"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"title":"Unknown or Not reported"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"272"}]}],"title":"ECOG PS 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"230"}]}],"title":"ECOG PS 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"98"}]}],"title":"ECOG PS 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"9"}]}],"title":"ECOG PS 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Not Reported"}],"description":"ECOG PS, a 6-item scale to assess disease progression, daily functioning, and appropriate treatment and prognosis. Scale: 0-5, with 0= Fully active, able to carry on all pre-disease performance without restriction and 5=Death.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"92"}]}],"title":"Primary Resistance"},{"categories":[{"measurements":[{"groupId":"BG000","value":"192"},{"groupId":"BG001","value":"190"},{"groupId":"BG002","value":"382"}]}],"title":"Acquired Resistance"},{"categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"132"}]}],"title":"Intolerance"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}],"title":"Missing"}],"description":"Failure on prior treatment with imatinib due to either resistance to or intolerance of imatinib. Resistance: no hematologic response after a ≥ 4-week treatment or a ≥ 50% increase in blasts after a 2-week treatment (primary resistance); achieved a hematologic response, no longer met criteria consistently on all assessments over a consecutive 2-week period while receiving an imatinib (acquired resistance); progressed while on treatment. Intolerance: Grade ≥ 3 non-hematologic toxicity or a Grade 4 hematologic toxicity lasting for \\> 2 weeks leading to discontinuation of therapy or dose decrease.","paramType":"NUMBER","title":"Imatinib Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"158"},{"groupId":"BG001","value":"159"},{"groupId":"BG002","value":"317"}]}],"title":"Accelerated Phase CML"},{"categories":[{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"149"}]}],"title":"Blast Phase CML - Myeloid"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"61"}]}],"title":"Blast Phase CML - Lymphoid"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"84"}]}],"title":"Ph+ ALL"}],"description":"Chronic Myelogenous Leukemia (CML) consists of a chronic phase lasting three to six years, followed by transformation to an accelerated phase (AP) and blast phases (myeloid and Lymphoid) of much shorter duration. The Philadelphia chromosome (Ph+) status was documented by cytogenetic analysis or by Fluorescent-In Situ Hybridization (FISH) for the presence of a protein kinase (BCR-ABL) on peripheral blood (PB) cells or bone marrow (BM) samples.","paramType":"NUMBER","title":"Participants by Disease Phase","unitOfMeasure":"participants"}],"populationDescription":"Randomized Population analyzed. Baseline data are based on what participants were randomized to receive and not what they actually received."}